Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Article in English | MEDLINE | ID: mdl-38722173

ABSTRACT

Benign endobronchial tumors are rare clinical entities characterized by considerable variability in etiology and clinical presentation. The authors report four cases of endobronchial hamartomas treated and followed up from 2018 to 2023. Three of these cases, with identical endobronchial localization in the right lower lobe, were radically treated in flexible bronchoscopy with the only use of biopsy forceps. Another case with a different localization in the left main bronchus was treated with a laser through rigid bronchoscopy. In addition, the authors outline the main interventional pulmonological strategies for the treatment of benign tumors with endobronchial growth based on the existing literature.

3.
Article in English | MEDLINE | ID: mdl-37781758

ABSTRACT

Dear Editor, we have read with interest the case reported by Rotolo et al.  (published in February 2023 as Early Access) concerning the surgical management of tracheoesophageal fistula (TEF) in a COVID-19 patient treated with prolonged mechanical ventilation for severe respiratory failure.

4.
Respirol Case Rep ; 11(5): e01112, 2023 May.
Article in English | MEDLINE | ID: mdl-37065167

ABSTRACT

Conventional transbronchial needle aspiration (cTBNA) remains a basic technique that must be part of the bronchoscopists expertise. In cases where EBUS is not available, cTBNA must be kept in mind: 'the old bull knows best'.

5.
Ann Thorac Cardiovasc Surg ; 28(6): 377-380, 2022 Dec 20.
Article in English | MEDLINE | ID: mdl-36058880

ABSTRACT

We present a case of surgical management of a tracheoesophageal fistula (TEF) following prolonged intubation. After transverse tracheal division and retraction of the distal stump, direct closure of the esophageal defect and repair of the membranous tracheal defect using a synthetic bioabsorbable patch were performed, followed by interposition of muscle flap between the suture lines and tracheal reconstruction. Large TEFs, without tracheal stenosis or circumferential airway defect, associated with marked peritracheal inflammation, may be treated with this alternative tracheoplastic technique in patients deemed not suitable for tracheal resection and anastomosis.


Subject(s)
Plastic Surgery Procedures , Tracheoesophageal Fistula , Humans , Tracheoesophageal Fistula/diagnostic imaging , Tracheoesophageal Fistula/etiology , Tracheoesophageal Fistula/surgery , Treatment Outcome , Trachea/diagnostic imaging , Trachea/surgery , Plastic Surgery Procedures/adverse effects
6.
Monaldi Arch Chest Dis ; 93(3)2022 Sep 20.
Article in English | MEDLINE | ID: mdl-36128929

ABSTRACT

Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) that is approved as first-line treatment in adult patients with ALK-positive non-small cell lung cancer (NSCLC) and as second-line in patients previously treated with crizotinib, and has been shown in the literature to significantly prolong progression-free survival compared to chemotherapy in patients with advanced non-small cell lung cancer. The authors describe a clinical case of a 24-year-old woman with malignant massive pleural effusion caused by ALK rearranged pulmonary adenocarcinoma with pleural and pericardial metastasis, in which, despite a dramatic clinical debut, the correct and timely management of the diagnostic and therapeutic path allowed for extraordinary therapeutic success.


Subject(s)
Adenocarcinoma of Lung , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Adult , Female , Humans , Young Adult , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Anaplastic Lymphoma Kinase/genetics , Anaplastic Lymphoma Kinase/therapeutic use , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/therapeutic use , Adenocarcinoma of Lung/drug therapy , Adenocarcinoma of Lung/genetics
7.
Case Rep Oncol ; 15(1): 300-304, 2022.
Article in English | MEDLINE | ID: mdl-35529285

ABSTRACT

We report an unusual mediastinal recurrence along descending thoracic aorta during oncologic follow-up in a 47-year-old female smoker issued by lung adenocarcinoma with a history of left lower lobectomy and lingulectomy en bloc followed by adjuvant chemotherapy for stage III A-N2. Regional recurrence occurring along the staple line was suspected and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) combined to PET/CT allowed to reach definitive tissue diagnosis. High focal hypermetabolic activity on PET/CT at the site of suspect recurrence was necessary to check the lesion sampling by EBUS-TBNA.

8.
Monaldi Arch Chest Dis ; 92(3)2021 Dec 16.
Article in English | MEDLINE | ID: mdl-34918499

ABSTRACT

Pulmonary hamartomas represent the most frequent family of benign lung tumors that typically involve the lung parenchyma and only rarely grow as endobronchial tumors. The elective treatment of endobronchial hamartoma is the bronchoscopic resection, and in those cases in which tumor extension and localization makes it not possible, surgical treatment must be evaluated. Patients with symptomatic COVID-19, hospitalized, frequently undergo a chest CT scan and in some cases, occasional findings may emerge, requiring diagnostic investigations such as bronchoscopy and interventional pulmonology procedures. Therefore, in such a delicate pathological condition, such as COVID-19, the need to perform bronchoscopy and interventional pulmonology procedures, minimizing the risk of viral transmission and ensuring necessary assistance, represents a great challenge for pulmonologists. In this article authors describe, for the first time in literature, a rare case of endobronchial hamartoma, radically resected using a single use bronchoscope, in a young female patient hospitalized for symptomatic COVID-19.


Subject(s)
Bronchial Diseases , COVID-19 , Hamartoma , Lung Neoplasms , Bronchial Diseases/pathology , Bronchoscopes , Bronchoscopy/methods , Female , Hamartoma/diagnosis , Hamartoma/pathology , Hamartoma/surgery , Humans
9.
Case Rep Oncol ; 14(3): 1616-1620, 2021.
Article in English | MEDLINE | ID: mdl-34950005

ABSTRACT

Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2 young women showing malignant pleural effusion secondary to advanced ALK-rearranged lung adenocarcinoma. This report shows that for patients with EGFR mutations in advanced lung adenocarcinoma-associated malignant pleural effusion, complete response to EGFR TKI inhibitor can be observed mostly if pleural effusion and primary lung adenocarcinoma show the same EGFR mutation status.

10.
Tumori ; 107(6): NP91-NP93, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34134548

ABSTRACT

Malignant central airway obstruction is a life-threatening condition that often causes respiratory failure. In many cases, treatment of tumor in rigid bronchoscopy must be performed urgently, soothing respiratory symptoms and improving patient quality of life, in many cases reducing time to and allowing application of oncologic therapies. Immuno-oncologic therapies target the immune system selectively and are therefore much less toxic than standard chemotherapies, sometimes leading to outstanding results in advanced cancers for which there were no effective treatments until a few years ago. This report shows the effect of the joint application of rigid bronchoscopy and targeted immunotherapy in an emergency scenario, resulting in an unexpected extraordinary therapeutic success.


Subject(s)
Adenocarcinoma of Lung/diagnosis , Adenocarcinoma of Lung/drug therapy , Bronchoscopy , Emergency Medical Services , Immunotherapy , Adenocarcinoma of Lung/complications , Adenocarcinoma of Lung/etiology , Airway Obstruction/diagnosis , Airway Obstruction/etiology , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/adverse effects , Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bronchoscopy/methods , Disease Management , Female , Humans , Immunotherapy/methods , Middle Aged , Molecular Targeted Therapy , Symptom Assessment , Tomography, X-Ray Computed , Treatment Outcome
11.
Monaldi Arch Chest Dis ; 91(2)2021 Mar 02.
Article in English | MEDLINE | ID: mdl-33666070

ABSTRACT

Severe Acute Respiratory Syndrome due to Coronavirus-19 (SARS-CoV-2) is caused by combined alveolar-capillary lung damage, with bilateral pneumonia and thrombosis, which often causes respiratory failure. Proper COVID-19 management requires high skills in airway control and the need to perform aerosol-generating procedures such as bronchoscopy, which can increase the possibility of virus spreading among healthcare professionals. In an epidemiologically delicate moment, the multidisciplinary decision on "WHEN, HOW and WHY" to perform bronchoscopies minimizing the risk of COVID-19 transmission, represented a great challenge for all specialists engaged in bronchoscopic procedures. In this work authors want to share all technical aspects of 87 videobronchoscopies performed in confirmed or suspected COVID-19 patients, from 3rd to 6th January 2020, describing the reason, the organizational and operational model and patients characteristics. Was also evaluated the impact of high-risk procedures such as bronchoscopy on the personnel involved. The disclosure of all technical details, represents, in the opinion of the authors, an important contribution, capable of providing support to all physicians engaged in bronchoscopy procedures in confirmed or suspected COVID-19 patients.


Subject(s)
Airway Management , Bronchoscopy , COVID-19/prevention & control , Infection Control/organization & administration , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Bronchoscopes , COVID-19/diagnosis , COVID-19/transmission , Humans , Patient Selection , Personal Protective Equipment
12.
Monaldi Arch Chest Dis ; 90(1)2020 Apr 15.
Article in English | MEDLINE | ID: mdl-32293166

ABSTRACT

Trans-bronchial needle aspiration allows lymph node sampling in several thoracic conditions; the ability of Rapid On-Site Evaluation (ROSE) to predict the final diagnosis in this setting has not been well characterized. We performed a retrospective study to establish the utility of ROSE in the diagnosis of thoracic diseases with mediastinal lymph node involvement. We retrospectively reviewed 297 patients with hilar-mediastinal lymph node enlargement detected at CT scan from January 2013 to April 2016. 201 patients underwent conventional TBNA; in 96 patients, TBNA procedure was performed by on-site presence of a team of pathologists and research morphologists. Lung neoplasms, sarcoidosis, infections and lymphoma were the most common diseases diagnosed with TBNA samples. TBNA simultaneously performed in combination with ROSE produced an increase in percentage of appropriate samples compared to single cTBNA (adequate samples cTBNA vs ROSE-TBNA: 73% vs 81%; p<0.05). Our observations indicate an increase in adequacy of fine needle aspirations and increased diagnostic yield in the ROSE group. In conclusions, ROSE may serve to reduce procedure time and enhance sample triaging therefore limiting the need for further invasive diagnostic testing.


Subject(s)
Bronchoscopy/methods , Endoscopic Ultrasound-Guided Fine Needle Aspiration/methods , Lymph Nodes/pathology , Sarcoidosis/diagnosis , Aged , Endoscopic Ultrasound-Guided Fine Needle Aspiration/trends , Female , Humans , Infections/pathology , Italy/epidemiology , Lung Neoplasms/pathology , Lymph Nodes/diagnostic imaging , Lymphadenopathy/pathology , Lymphoma/pathology , Male , Mediastinum/pathology , Middle Aged , Operative Time , Retrospective Studies , Sarcoidosis/pathology , Specimen Handling/methods , Thoracic Diseases/pathology , Tomography, X-Ray Computed/methods
13.
Int J Surg ; 33 Suppl 1: S30-5, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27255131

ABSTRACT

Carcinoids are tumors that originate from diffuse neuroendocrine system cells (APUD cells) and represent 1-2% of all pulmonary tumors. Although surgical resection remains the mainstay of treatment, bronchoscopic radical resection of typical carcinoids in selected cases exhibiting endoluminal growth and small implant base has also been explored. Bronchoscopic removal of endobronchial lesions may also reduce the risk of post-obstructive infections and improve pulmonary function, allowing the patient to undergo surgery in better clinical and respiratory state. In this paper we have evaluated the impact on surgical planning and outcome of preoperative bronchoscopic resection in treatment of endobronchial typical carcinoids. Our observations further support the role of bronchoscopic treatment before surgery in endobronchial typical carcinoids.


Subject(s)
Bronchial Neoplasms/surgery , Bronchoscopy , Carcinoid Tumor/surgery , Adolescent , Adult , Aged , Bronchial Neoplasms/diagnostic imaging , Carcinoid Tumor/diagnostic imaging , Female , Humans , Male , Middle Aged , Pneumonectomy , Preoperative Care , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...